Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.
about
Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain.A review of augmentation therapy for alpha-1 antitrypsin deficiency.Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes.alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understandingChronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2003.Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisThe promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency.Multilineage transduction of resident lung cells in vivo by AAV2/8 for α1-antitrypsin gene therapy.Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies.Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options?Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.Efficient inhibition of human leukocytic elastase by means of α1-antitrypsin/peptide complexes.Quercetin treatment changes fluxes in the primary metabolism and increases culture longevity and recombinant α₁-antitrypsin production in human AGE1.HN cells.Primary metabolism in the new human cell line AGE1.HN at various substrate levels: increased metabolic efficiency and α1-antitrypsin production at reduced pyruvate load.Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization.Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy.α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis.Deficiência de alfa-1 antitripsina: diagnóstico e tratamento
P2860
Q33644019-C0B3A848-B638-41C4-93BD-00DA83D4CA9CQ34268108-692CAD5C-53F0-4305-A517-75EEEC52AC1DQ35063726-E863F459-5CF8-4F66-9042-64448C680BE5Q35536847-202CDFE0-8C0A-4828-AE1E-0694AB0C7526Q35626624-9DF7AF09-D841-4FC9-BCD8-24B2FB92A1F6Q36062323-0E735858-EDEB-4277-AC5E-6246D565BA03Q36966036-AED9D611-AFAC-4280-855F-CEDA06296509Q37051733-5E319CDB-6F58-4057-B778-8722AE070C0AQ37303247-FFE11A96-8F54-4706-82EF-C5CF59A0FAA6Q37474870-A1EF038A-0E5B-4401-9D43-4ABDB897A0A4Q37614554-73A45FEF-851E-4F09-A1F8-1280D1500A47Q37774788-C5861960-D3A3-4E00-8B99-24F91822711BQ38604630-20C10EF7-AE13-40BB-9955-6365539B299CQ39175595-8229B94F-79D4-4072-82AF-A8316D666790Q39421619-193E49EA-F5DA-4827-A0E6-22E888618079Q39490117-72AFDB8B-D214-4BB8-A19A-3AB6224C8170Q39899143-8BB7F148-E6E5-4753-96B6-3CAFE8B4004EQ47703811-7F3F0206-A731-4C1B-BE2D-E9C123E1C36DQ51182286-3AA208F0-399A-47E9-A5FC-B26B06A19164Q51651054-7D52BB94-3E51-49B2-BCF1-6270DF1325A6Q53075740-853019E9-C823-4206-9089-1AFC0E51A13CQ53214902-6FB06560-76FA-4265-AF8F-27B13DD946DCQ57778139-B768767C-E736-43D8-8CE2-3524B2FE008C
P2860
Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cost-effectiveness analysis of ...... alpha1-antitrypsin deficiency.
@en
Cost-effectiveness analysis of ...... alpha1-antitrypsin deficiency.
@nl
type
label
Cost-effectiveness analysis of ...... alpha1-antitrypsin deficiency.
@en
Cost-effectiveness analysis of ...... alpha1-antitrypsin deficiency.
@nl
prefLabel
Cost-effectiveness analysis of ...... alpha1-antitrypsin deficiency.
@en
Cost-effectiveness analysis of ...... alpha1-antitrypsin deficiency.
@nl
P2093
P2860
P1476
Cost-effectiveness analysis of ...... alpha1-antitrypsin deficiency
@en
P2093
James K Stoller
Kenneth M Shermock
Thomas R Gildea
P2860
P304
P356
10.1164/RCCM.200209-1035OC
P407
P577
2003-02-05T00:00:00Z